Here attached you may find the takeaways of the guidelines for patients and for clinicians. takeaways for patients: https://kdigo.org/wp-content/uploads/2018/03/Top-10-Takeaways-Patients.pdf takeaways for clinicians: https://kdigo.org/wp-content/uploads/2018/03/Top-10-Takeaways-Clinicians.pdf
Tag: Diabetes
Factors associated with social #isolation and being homebound among #older patients with #diabetes: a cross-sectional study
We aimed at investigating factors associated with social isolation and being homebound in older patients with diabetes.. ..Social isolation was defined as indulging in less than one interaction per week with individuals other than cohabiting family members. We defined homebound as going outside home less than once a day. To identify factors associated with social… Continue reading Factors associated with social #isolation and being homebound among #older patients with #diabetes: a cross-sectional study
Five-Year Patterns of #Diabetic #Retinopathy Progression in US Clinical Practice
To characterize the natural course of diabetic retinopathy (DR) in contemporary clinical practice. Patients and Methods: This was a retrospective analysis of US claims data collected between January 1, 2006, and April 30, 2017. Patients aged ≥ 18 years with continuous medical and prescription insurance coverage for 18 months before DR diagnosis (index date) and… Continue reading Five-Year Patterns of #Diabetic #Retinopathy Progression in US Clinical Practice
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown. ..During a median follow-up of 2.6 years, a primary outcome event occurred in 504 of 2833 patients (17.8%) in the finerenone… Continue reading Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
#Empagliflozin treatment effects across categories of baseline #HbA1c, body #weight and blood #pressure as an add‐on to metformin in patients with type 2 diabetes
In EMPA‐REG MET, in patients with type 2 diabetes mellitus (T2DM) on stable background metformin (≥1500 mg/day), empagliflozin versus placebo significantly improved glycated haemoglobin (HbA1c), body weight (BW), and systolic blood pressure (SBP) over 24 and ≤76 weeks. This analysis investigated empagliflozin treatment effects by baseline cardio‐metabolic factors.. ..In total, 637 patients (56.7% males; mean [SD]… Continue reading #Empagliflozin treatment effects across categories of baseline #HbA1c, body #weight and blood #pressure as an add‐on to metformin in patients with type 2 diabetes
Additive effects of green #tea and #coffee on all-cause mortality in patients with type 2 #diabetes mellitus: the Fukuoka Diabetes Registry
The impact of consuming green tea or coffee on mortality in patients with diabetes is controversial. We prospectively investigated the impact of each beverage and their combination on mortality among Japanese patients with type 2 diabetes.. ..During the follow-up period, 309 participants died. The consumption of green tea, coffee, and a combination of the beverages… Continue reading Additive effects of green #tea and #coffee on all-cause mortality in patients with type 2 #diabetes mellitus: the Fukuoka Diabetes Registry
644 – Development of noninvasive #diabetes monitoring method using #tear samples
To prevent diabetic complications, strict glucose control and frequent monitoring of blood glucose levels are necessary. However, all currently available methods for blood glucose monitoring, including the finger prick method, are invasive. Therefore, noninvasive blood glucose monitoring approaches have been investigated, but until date, none has been found to be a suitable substitute for direct… Continue reading 644 – Development of noninvasive #diabetes monitoring method using #tear samples
#Dapagliflozin in Patients with Chronic #Kidney Disease
Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.. ..The independent data monitoring committee recommended stopping the trial because of efficacy. Over a median of 2.4 years, a primary outcome… Continue reading #Dapagliflozin in Patients with Chronic #Kidney Disease
Once-Weekly #Insulin for Type 2 #Diabetes without Previous Insulin Treatment
It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. Insulin icodec is a basal insulin analogue designed for once-weekly administration that is in development for the treatment of diabetes We conducted a 26-week, randomized, double-blind, double-dummy, phase 2 trial… Continue reading Once-Weekly #Insulin for Type 2 #Diabetes without Previous Insulin Treatment
2 Medical News 